A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia

Am J Hematol. 2020 Nov;95(11):E310-E313. doi: 10.1002/ajh.25968. Epub 2020 Sep 8.

Authors

Christopher Pleyer¹, Xin Tian², Shakuntala Rampertaap³, Rui Mu¹, Susan Soto¹, Jeanine Superata¹, Erika Gaglione¹, Clare Sun¹, Jennifer Lotter¹, Maryalice Stetler-Stevenson⁴, Constance M Yuan⁴, Irina Maric³, Stefania Pittaluga⁴, Sergio Rosenzweig³, Thomas Fleisher³, Adrian Wiestner¹, Inhye E Ahn¹

Affiliations

¹ Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
² Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
³ Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
⁴ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / administration & dosage
Adenine / adverse effects
Adenine / analogs & derivatives
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Disease-Free Survival
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / blood
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / mortality
Male
Piperidines / administration & dosage
Piperidines / adverse effects
Survival Rate
Vidarabine / administration & dosage
Vidarabine / adverse effects
Vidarabine / analogs & derivatives

Substances

Piperidines
ibrutinib
Vidarabine
Adenine
fludarabine

Grants and funding